Bringing the Oncology Community Together

Dr. Rizvi on PD-1 and PD-L1 Inhibitors in Lung Cancer

Naiyer A, Rizvi,MD
Published Online: Sunday, November 10, 2013

Naiyer A. Rizvi, MD, an associate attending physician, Memorial Sloan-Kettering Cancer Center, discusses PD-1 and PD-L1 antibodies in development for the treatment of lung cancer.

Rizvi says the anti-PD-1 antibodies nivolumab and MK-3475, and the anti-PD-L1 antibody MPDL3280A, are all being developed as treatments for stage IV lung cancer. Early studies of these agents have shown a response rate in the 20% range in patients with heavily pre-treated lung cancer who are resistant to chemotherapy and have failed all standard therapies. Rizvi says a 20% response rate is very encouraging for this group of patients.

Many of these patients have also showed durable responses, Rizvi says. Recently, the data from the nivolumab trial were updated to show a 2-year survival of 24%, which Rizvi says is a very high number for that patient population.

<<< View coverage from the New York Lung Cancer Symposium

Related Articles
Pancoast Tumors of the Lung: Improved Results
Every patient with a pancoast tumor of the lung should be evaluated by a Pancoast-experienced thoracic surgeon (and neurosurgeon) before ruling out surgery, and before starting induction therapy.
Next-Generation Targeted Therapies in NSCLC
In this segment, panelists discuss the number of early-phase clinical trials that have demonstrated impressive efficacy for next-generation ALK and EGFR inhibitors for patients with non-small cell lung cancer.
PD-L1 Predictive of Response to MK-3475 in Melanoma and NSCLC
PD-L1 levels adequately predict response and clinical outcomes for PD-1 inhibitor MK-3475 in patients with non-small cell lung cancer (NSCLC) and melanoma
Most Popular Right Now
More Reading
External Resources

American Journal of Managed Care
HCPLive
PainLive
Pharmacy Times
Physicians' Education Resource
Physician's Money Digest
Specialty Pharmacy Times
TargetedOnc
OncLive Resources

Archives
Blogs
OncLive TV
Oncology Nurses
Publications
Specialties
Web Exclusives


About Us
Advertise
Advisory Board
Contact Us
Forgot Password
Privacy Policy
Terms & Conditions
Intellisphere, LLC
666 Plainsboro Road
Building 300
Plainsboro, NJ 08536
P: 609-716-7777
F: 609-716-4747

Copyright OncLive 2006-2014
Intellisphere, LLC. All Rights Reserved.